AB Science SA

AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037

18 Apr 2023 09:55:51 By Nasdaq GlobeNewswire

AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline

12 Apr 2023 09:23:23 By Nasdaq GlobeNewswire

AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada

04 Apr 2023 09:10:02 By Nasdaq GlobeNewswire

AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET

15 Mar 2023 10:05:03 By Nasdaq GlobeNewswire

AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy

27 Feb 2023 23:03:43 By Nasdaq GlobeNewswire

AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank

31 Jan 2023 09:17:01 By Nasdaq GlobeNewswire

AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis

29 Dec 2022 09:08:58 By Nasdaq GlobeNewswire

Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland

27 Dec 2022 10:04:45 By Nasdaq GlobeNewswire

AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank

22 Dec 2022 09:10:29 By Nasdaq GlobeNewswire

AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)

13 Dec 2022 09:08:12 By Nasdaq GlobeNewswire

AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease

21 Nov 2022 09:09:53 By Nasdaq GlobeNewswire

AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease

10 Oct 2022 09:04:50 By Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2022 and provides an update on its activities

30 Sep 2022 09:39:50 By Nasdaq GlobeNewswire

AB Science - Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19

14 Sep 2022 09:21:04 By Nasdaq GlobeNewswire

AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS

24 Aug 2022 10:06:59 By Nasdaq GlobeNewswire

AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy

07 Jun 2022 08:45:45 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS

26 May 2022 13:46:10 By Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2021 and provides an update on its activities

29 Apr 2022 09:33:38 By Nasdaq GlobeNewswire

AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)

27 Apr 2022 23:01:11 By Nasdaq GlobeNewswire

Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)

29 Mar 2022 10:57:17 By Nasdaq GlobeNewswire